ERICA GIBSON: Open Payments
NPI 1235522780 · CABOT, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,569 in 89 payments from 14 companies in 2025. Trend: 2023 $2,357 · 2024 $2,338 · 2025 $1,569
Food & beverage: $1,569
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 26 | $449 |
| ABBVIE INC. | 13 | $252 |
| Lilly USA, LLC | 13 | $221 |
| Phathom Pharmaceuticals, Inc. | 7 | $107 |
| Novo Nordisk Inc | 6 | $92 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $84 |
| GlaxoSmithKline, LLC. | 4 | $76 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $70 |
| Amgen Inc. | 4 | $62 |
| Antares Pharma, Inc. | 2 | $41 |
Products named: AIRSUPRA, MOUNJARO, VRAYLAR, JARDIANCE, BREZTRI, VOQUEZNA, XIFAXAN, TRELEGY ELLIPTA.
Industry payments across AR — which companies pay providers there.
